PfSPZ-LARC2 Vaccine
Malaria Prevention (*Plasmodium falciparum*)
Phase 1Active
Key Facts
About Sanaria
Sanaria is a pioneering private biotech developing a novel class of malaria vaccines based on live, attenuated sporozoites (PfSPZ). The company has advanced multiple candidates into clinical development, with its PfSPZ-LARC2 vaccine representing a potential single-dose, transformative solution. Sanaria operates through a global collaborative model via the International PfSPZ Consortium (i-PfSPZ-C), positioning itself at the forefront of the fight for malaria elimination, targeting both individual protection and community-wide transmission interruption.
View full company profileTherapeutic Areas
Other Malaria Prevention (*Plasmodium falciparum*) Drugs
| Drug | Company | Phase |
|---|---|---|
| PfSPZ Vaccine | Sanaria | Phase 2 |